A Randomized, Open-label, Phase 3 Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma.

Trial Profile

A Randomized, Open-label, Phase 3 Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma.

Completed
Phase of Trial: Phase III

Latest Information Update: 04 May 2017

At a glance

  • Drugs Carfilzomib (Primary) ; Cyclophosphamide; Dexamethasone; Prednisolone
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Acronyms FOCUS
  • Sponsors Amgen; Onyx Pharmaceuticals
  • Most Recent Events

    • 23 Nov 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 05 Mar 2015 Planned End Date changed from 1 Jan 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
    • 13 Aug 2014 Top-line results published in Amgen and Onyx Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top